Clinic Roundup

Millennium, of Cambridge, Mass., a unit of the Takeda Oncology Co., presented data from an ongoing Phase II trial of Aurora A kinase inhibitor MLN8237 for B-cell and T-cell non-Hodgkin lymphoma. In 41 evaluable patients, MLN8237 treatment resulted in a 32 percent overall response rate and a 12 percent complete response rate. The data were presented at the International Congress on Malignant Lymphoma.